Cancer Pain

NIH Scientists Develop Promising Treatment for Intractable Cancer Pain

NIH scientists have conducted a successful first-in-human trial of resiniferatoxin (RTX), a plant-derived, non-addictive therapy that significantly reduces intractable cancer pain and opioid use, with potential applications for other pain conditions. RTX works by selectively blocking pain signals without affecting other sensations, offering a promising new approach to pain management.